Patients Likely To Rotate Therapies
Cypress, Forest NDA In FMS Puts Drug In Line For 'Churn'
By Randall Osborne
Monday, January 7, 2008
When Pfizer Inc. won U.S. approval of its alpha-2 delta ligand Lyrica, people with fibromyalgia syndrome (FMS) gained their first official therapy for the painful, head-to-toe disorder, which brings a dreary lineup of added symptoms that include fatigue, muscle stiffness, cognitive dysfunction and insomnia. (BioWorld Financial Watch)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.